The role of the Molecular Pathology Core is to support investigators in the Program Project Grant by providing dedicated molecular biological analyses for effective assessment of disease states, the molecular basis of response to therapy both in patients and in animal models, and the analysis of immune reconstitution following transplant interventions. The services provided by this Core are those that extend beyond routine preclinical studies and standard clinical care. This Core provides molecular testing for projects that monitor treatment outcomes, detect eariy disease recurrence and minimal disease states. Rapid and quantitative assessment of experimental therapies is necessary for accelerated and accurate analyses of potential efficacy. Quantitative assessment of minimal residual disease will be performed using TaqMan chemistry for a robust assessment of disease response and potential recurrence on clinical specimens. The core will utilize novel, massively parallel next generation sequencing technology in addition to the standard real-time PCR methods to improve detection of minimal residual disease and provide an assessment of immune reconstitution. The centralized performance of the molecular procedures by this Core will avoid duplication of efforts in the program and ensure timely, efficient and consistently high quality results.
The Molecular Pathology Core uses state of the art technologies to support investigators in the Program Project Grant by providing dedicated molecular biological analyses for effective assessment of disease states, the molecular basis of response to therapy both in patients and in animal models, and the analysis of immune reconstitution following transplant interventions. Centralized performance of the molecular procedures by this Core will avoid duplication of efforts in the program and ensure timely, efficient and consistently high quality results.
|Chen, Yi-Bin; Efebera, Yvonne A; Johnston, Laura et al. (2017) Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant 23:625-634|
|Spinner, Michael A; Fernández-Viña, Marcelo; Creary, Lisa E et al. (2017) HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Adv 1:1347-1357|
|Costa, Helio A; Neal, Joel W; Bustamante, Carlos D et al. (2017) Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer. Mol Diagn Ther 21:431-436|
|Xu, Liwen; You, Xiaoqing; Zheng, PingPing et al. (2017) Methodologic Considerations in the Application of Next-Generation Sequencing of Human TRB Repertoires for Clinical Use. J Mol Diagn 19:72-83|
|Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125|
|Paul, Jed; Sahaf, Bita; Perloff, Spenser et al. (2016) High-throughput allogeneic antibody detection using protein microarrays. J Immunol Methods 432:57-64|
|Ozawa, Michael G; Bhaduri, Aparna; Chisholm, Karen M et al. (2016) A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. Mod Pathol 29:1212-20|
|Kelley, Todd W; Arber, Daniel A; Gibson, Christine et al. (2016) Template for Reporting Results of Biomarker Testing of Specimens From Patients With Myeloproliferative Neoplasms. Arch Pathol Lab Med 140:675-7|
|Sen, Nandini; Arvin, Ann M (2016) Dissecting the Molecular Mechanisms of the Tropism of Varicella-Zoster Virus for Human T Cells. J Virol 90:3284-7|
|Khodadoust, M S; Luo, B; Medeiros, B C et al. (2016) Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia 30:947-50|
Showing the most recent 10 out of 304 publications